Cetraxal Otic
ciprofloxacin otic
Treatment for Otitis ExternaSalvat Seeks FDA Approval for its Cetraxal Otic (Ciprofloxacin Otic) 0.2% Solution, for the Treatment of External Otitis
BARCELONA, Spain, April 18, 2005 -- Salvat announce plans to file their Cetraxal Otic solution, with its convenient, single-dispensing container (SDC) format, with the FDA.
The efficacy and safety of the treatment has been assessed in a 630 patient clinical trial, which will be the basis for their application in the 2nd quarter of 2005.
"We combined the advantages of a proven, effective antibiotic with a simple, accurate form of administration. The idea behind our product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the paediatric population. We are convinced that finding the right commercial partner in the US will help us to bring the benefits of this new product to a great number of patients." said Jordi Julve, COO of Salvat.
About Salvat
Salvat is an independent, privately owned, Spanish pharmaceutical
group closely identified with technological innovation and strongly
committed to R&D.
Related Articles:
Salvat Announces the FDA Acceptance of NDA for its Cetraxal Otic Solution - September 14, 2005
SALVAT Files NDA for its Cetraxal Otic - Ciprofloxacin Otic- 0.2% Solution, for the Treatment of External Otitis - June 10, 2005
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
